FDA briefing documents appear to be positive in advance of a meeting of the FDA Antiviral Drugs Advisory Committee scheduled for Friday to discuss approval of sofosbuvir in hepatitis C virus (HCV). Questions for the panelists focus on optimal duration of therapy in genotype 2 and 3 patients. The FDA’s documents suggest that the agency is favorably inclined toward approval of the drug, and sees no significant safety issues with it.